{
  "section": "efficacy_analysis",
  "rating": "POOR",
  "status": "fail",
  "endpoint_evaluated": "Progression-Free Survival (PFS)",
  "extraction_validation": {
    "sections_read": [
      "8.2.2",
      "8.2.2.3"
    ],
    "elements_per_section": {
      "component_name": 1
    },
    "elements_extracted": 3,
    "elements_in_evaluation_table": 3,
    "elements_in_missing_from_generated_sap": 0,
    "counts_match": true
  },
  "evaluation_table": [
    {
      "component": "Endpoint Name",
      "evaluation_type": "exact_match",
      "original_sap_text": "Progression-free Survival",
      "generated_sap_text": "Progression-Free Survival (PFS)",
      "protocol_text": "progression-free survival (PFS)",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "The endpoint name matches the Original SAP."
    },
    {
      "component": "Endpoint Definition",
      "evaluation_type": "semantic",
      "original_sap_text": "PFS is defined as time from randomization to determined PD/recurrence or death from any cause (whichever occurs first). PD/recurrence or death that occurred on or before beginning another new anticancer therapy will be regarded as an event.\n...\nPFS (months) = (Date of Event/Censoring \u2013 Date of Randomization +1)/30.4",
      "generated_sap_text": "Progression-Free Survival (PFS) is defined as the time from the date of randomization until the date of the first documented occurrence of progressive disease (PD)... or death from any cause, whichever occurs first.\n...\nPFS (days) = [Date of Event or Censoring] \u2013 [Date of Randomization] + 1.\nFor analysis in months, days will be converted as: PFS (months) = PFS (days) / 30.4375.",
      "protocol_text": "PFS: the time from randomization until PD/recurrence or death due to any cause, whichever occurs first",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "contradiction",
      "omitted_content": "none",
      "omission_impact": "potential",
      "result": "problem",
      "issue_type": "contradiction_original",
      "severity": "minor",
      "reasoning": "The Original SAP explicitly specifies a conversion factor of 30.4 for months. The Generated SAP uses 30.4375. While 30.4375 is the exact result of 365.25/12 (which appears in a parenthetical in the Original SAP), the Original SAP explicitly mandates dividing by 30.4 in the formula."
    },
    {
      "component": "Analysis Method",
      "evaluation_type": "semantic",
      "original_sap_text": "The median survival time and its corresponding 95% CI for each treatment group will be estimated using the Kaplan-Meier method. The 25th percentile and 75th percentile for the Survival times along with the corresponding 95% CI for the percentiles will also be displayed. The Brookmeyer-Crowley methodology will be used to construct the 95% CI for each percentile... In addition, the estimate of survival rates (at 6, 12, 24, 36 months for response duration, TTP, PFS and at 12, 24, 36 months for OS) will be displayed along with their corresponding 95% CI... In PFS and OS analyses, an adjusted stratified cox regression model will be used to estimate the hazard ratio and its 95% CI... using country, sex (female vs. male), disease status at baseline (recurrence vs. metastatic), and ECOG performance score at baseline (0 vs. 1) as stratification factors.",
      "generated_sap_text": "The distribution of PFS will be estimated for each treatment group using the Kaplan-Meier (KM) method. The following statistics will be presented:\n- Median PFS time with two-sided 95% confidence intervals (CIs) calculated using the Brookmeyer-Crowley method.\n- PFS rates at landmark time points (e.g., 6, 9, and 12 months) with corresponding 95% CIs.\n...\nThe hazard ratio (HR) and its associated 95% CI will be estimated using a stratified Cox proportional hazards model. The model will include treatment group as a fixed effect and will be stratified by... Country, Sex (Female vs. Male), Disease Status (Recurrence vs. Metastatic), ECOG performance score (0 vs. 1)",
      "protocol_text": "A time-to-event analysis will be undertaken for each of the response duration, TTP, PFS, and OS in the ITT and PP population; the median time and its corresponding 95% CI for each treatment group for each secondary endpoint of time-to-event analysis will be estimated using the Kaplan-Meier method.",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "contradiction",
      "omitted_content": "25th and 75th percentiles; specific landmark timepoints (24, 36 months)",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "contradiction_original",
      "severity": "minor",
      "reasoning": "The Generated SAP contradicts the Original SAP regarding landmark timepoints (Original: 6, 12, 24, 36 months; Generated: 6, 9, 12 months). Additionally, the Generated SAP omits the requirement to display the 25th and 75th percentiles with their 95% CIs."
    }
  ],
  "missing_from_generated_sap": [],
  "issues": [
    {
      "issue_type": "contradiction_original",
      "severity": "minor",
      "component": "Endpoint Definition (Month Conversion)",
      "original_sap_text": "Time-to-event in days will be converted to months by dividing the number of days by 30.4 (365.25 days/12 months).\n...\nPFS (months) = (Date of Event/Censoring \u2013 Date of Randomization +1)/30.4",
      "generated_sap_text": "For analysis in months, days will be converted as: PFS (months) = PFS (days) / 30.4375.",
      "protocol_text": null,
      "why_they_conflict": "The Original SAP explicitly defines the divisor as 30.4, whereas the Generated SAP uses 30.4375.",
      "description": "The Generated SAP uses a different conversion factor for days to months than the Original SAP.",
      "reasoning": "The Original SAP provides the exact formula using 30.4. Although 365.25/12 equals 30.4375, the explicit instruction is to divide by 30.4."
    },
    {
      "issue_type": "contradiction_original",
      "severity": "minor",
      "component": "Analysis Method (Landmark Timepoints)",
      "original_sap_text": "In addition, the estimate of survival rates (at 6, 12, 24, 36 months for response duration, TTP, PFS and at 12, 24, 36 months for OS) will be displayed along with their corresponding 95% CI.",
      "generated_sap_text": "PFS rates at landmark time points (e.g., 6, 9, and 12 months) with corresponding 95% CIs.",
      "protocol_text": null,
      "why_they_conflict": "Original SAP requires 6, 12, 24, and 36 months. Generated SAP lists 6, 9, and 12 months.",
      "description": "The Generated SAP specifies different landmark timepoints for PFS analysis than the Original SAP.",
      "reasoning": "The Original SAP has a specific list of timepoints including 24 and 36 months which are absent in the Generated SAP, while the Generated SAP adds 9 months which is not in the Original."
    },
    {
      "issue_type": "contradiction_original",
      "severity": "minor",
      "component": "Analysis Method (Percentiles)",
      "original_sap_text": "The 25th percentile and 75th percentile for the Survival times along with the corresponding 95% CI for the percentiles will also be displayed.",
      "generated_sap_text": "Median PFS time with two-sided 95% confidence intervals (CIs) calculated using the Brookmeyer-Crowley method.",
      "protocol_text": null,
      "why_they_conflict": "Original SAP explicitly requires 25th and 75th percentiles. Generated SAP omits them.",
      "description": "The Generated SAP omits the requirement to analyze and display the 25th and 75th percentiles.",
      "reasoning": "This is a specific analysis requirement in the Original SAP that is missing from the Generated SAP."
    }
  ],
  "extra_information_flagged": [
    {
      "content": "Stratified Log-rank Test",
      "generated_sap_text": "A two-sided stratified log-rank test will be used to compare the PFS distributions between the two treatment groups.",
      "contradicts": "no",
      "detail": "Original SAP does not explicitly mention a log-rank test for secondary endpoints (only Cox model and KM), but does not forbid it.",
      "reasoning": "The addition of a log-rank test is a standard statistical practice and does not contradict the requirement to perform Cox regression and KM analysis."
    }
  ],
  "reasoning": "The Generated SAP correctly identifies the endpoint and the primary analysis methods (KM, Stratified Cox). However, it introduces contradictions in the calculation details (month conversion factor) and specific reporting requirements (landmark timepoints). It also omits the requirement for 25th and 75th percentiles. While the Protocol does not specify these details (making the omissions acceptable in a vacuum), the Generated SAP contradicts the specific instructions provided in the Original SAP.",
  "summary": "The Generated SAP accurately captures the high-level analysis strategy for PFS but fails on specific details defined in the Original SAP. It uses a different month conversion factor (30.4375 vs 30.4), lists different landmark timepoints, and omits required percentile statistics."
}